Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Bebtelovimab  COVID-19 treatment studies for Bebtelovimab  C19 studies: Bebtelovimab  Bebtelovimab   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   All Outcomes   Recent:  
0 0.5 1 1.5 2+ Mortality 57% Improvement Relative Risk ICU admission 59% Hospitalization, COVID-19 56% Hospitalization, all cause 46% Progression -33% Molina et al. Bebtelovimab for COVID-19 EARLY Is early treatment with bebtelovimab beneficial for COVID-19? Retrospective 9,162 patients in the USA (April - October 2022) Lower hospitalization (p<0.0001) and higher progression (p=0.001) Molina et al., Int. J. Infectious Diseases, doi:10.1016/j.ijid.2023.04.396 Favors bebtelovimab Favors control

Real-World Evaluation of Bebtelovimab Effectiveness During the Period of COVID-19 Omicron Variants including BA.4/BA.5

Molina et al., International Journal of Infectious Diseases, doi:10.1016/j.ijid.2023.04.396
Molina et al., Real-World Evaluation of Bebtelovimab Effectiveness During the Period of COVID-19 Omicron Variants including.., International Journal of Infectious Diseases, doi:10.1016/j.ijid.2023.04.396
Apr 2023   Source   PDF  
  All Studies   Meta
Retrospective 3,739 patients treated with bebteloviman in the USA and matched controls, showing lower mortality and hospitalization with treatment, but higher emergency department visits.
Confounding by treatment propensity. This study analyzes a population where only a fraction of eligible patients received the treatment. Patients receiving treatment may be more likely to follow other recommendations, more likely to receive additional care, and more likely to receive adjuvant treatments that are not tracked in the data (e.g., nasal/oral hygiene [, (B)], vitamin D [ (C)], etc.) — either because the physician recommending bebtelovimab also recommended them, or because the patient seeking out bebtelovimab is more likely to be familiar with the efficacy of additional treatments. Therefore, these kind of studies may overestimate the efficacy of treatments.
Efficacy is variant dependent. In Vitro research suggests a lack of efficacy for omicron BQ.1.1 [Planas].
risk of death, 57.0% lower, RR 0.43, p = 0.14, treatment 3 of 3,739 (0.1%), control 11 of 5,423 (0.2%), NNT 816, adjusted per study, odds ratio converted to relative risk, propensity score matching, multivariable.
risk of ICU admission, 58.6% lower, RR 0.41, p = 0.05, treatment 6 of 3,739 (0.2%), control 21 of 5,423 (0.4%), NNT 441.
risk of hospitalization, 55.5% lower, RR 0.44, p < 0.001, treatment 38 of 3,739 (1.0%), control 107 of 5,423 (2.0%), NNT 105, adjusted per study, odds ratio converted to relative risk, COVID-19, propensity score matching, multivariable.
risk of hospitalization, 46.5% lower, RR 0.54, p < 0.001, treatment 48 of 3,739 (1.3%), control 116 of 5,423 (2.1%), NNT 117, adjusted per study, odds ratio converted to relative risk, all cause, propensity score matching, multivariable.
risk of progression, 32.6% higher, RR 1.33, p = 0.001, treatment 260 of 3,739 (7.0%), control 275 of 5,423 (5.1%), adjusted per study, odds ratio converted to relative risk, ED visit, propensity score matching, multivariable.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Molina et al., 16 Apr 2023, retrospective, USA, peer-reviewed, 11 authors, study period 6 April, 2022 - 11 October, 2022.
All Studies   All Outcomes   Submit Updates or Corrections
This PaperBebtelovimabAll
Real-World Evaluation of Bebtelovimab Effectiveness During the Period of COVID-19 Omicron Variants including BA.4/BA.5
Pharm.D. Kyle C Molina, MPSH Victoria Kennerley, MS Laurel E Beaty, MD Tellen D Bennett, PhD Nichole E Carlson, PhD David A Mayerij, BSN Jennifer L Peers, MS Seth Russell, MD Matthew K Wynia, MD, MHSc Neil R Aggarwal, MD, MPH Adit A Ginde
International Journal of Infectious Diseases, doi:10.1016/j.ijid.2023.04.396
This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Author Contributions AAG conceived and obtained funding for the study. KCM, VK LEB, NEC, NRA and AAG designed the study. VK, LEB, and NEC analysed the data. VK, LEB, TDB, NEC, DAM, and SR accessed and verified the data. KCM drafted the original version of the manuscript. All authors Conflict of Interest Statement The authors report no conflicts of interest.
Aggarwal, Beaty, Bennett, Change in Effectiveness of Sotrovimab for Preventing Hospitalization and Mortality for At-risk COVID-19 Outpatients During an Omicron BA.1 and BA.1.1-Predominant Phase, International Journal of Infectious Diseases
Aggarwal, Beaty, Bennett, Real World Evidence of the Neutralizing Monoclonal Antibody Sotrovimab for Preventing Hospitalization and Mortality in COVID-19 Outpatients, J Infect Dis
Arora, Kempf, Nehlmeier, Augmented neutralisation resistance of emerging omicron subvariants BA.2.12.1, BA.4, and BA.5, The Lancet Infectious Diseases
Austin, Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies, Pharm Stat
Dougan, Azizad, Chen, Bebtelovimab, alone or together with bamlanivimab and etesevimab, as a broadly neutralizing monoclonal antibody treatment for mild to moderate, ambulatory COVID-19, medRxiv, doi:10.1101/2022.03.10.22272100v1
Heinze, Schemper, A solution to the problem of separation in logistic regression, Statist Med
Heinze, logistf: Firth's Bias-Reduced Logistic Regression, R package version
Ho, Imai, King, Stuart, MatchIt: Nonparametric Preprocessing for Parametric Causal Inference, Journal of Statistical Software
Hoertel, Boulware, Sánchez-Rico, Burgun, Limosin, Prevalence of Contraindications to Nirmatrelvir-Ritonavir Among Hospitalized Patients With COVID-19 at Risk for Progression to Severe Disease, JAMA Network Open
Lim, Tignanelli, Hoertel, Boulware, Usher, Prevalence of Medical Contraindications to Nirmatrelvir/Ritonavir in a Cohort of Hospitalized and Nonhospitalized Patients With COVID-19, Open Forum Infect Dis
Lin, Hung, Lai, Wang, Chen, The impact of neutralizing monoclonal antibodies on the outcomes of COVID-19 outpatients: A systematic review and meta-analysis of randomized controlled trials, J Med Virol
Mccreary, Kip, Collins, Evaluation of Bebtelovimab for Treatment of Covid-19 During the SARS-CoV-2 Omicron Variant Era, Open Forum Infectious Diseases
Nguyen, Collins, Spence, Double-adjustment in propensity score matching analysis: choosing a threshold for considering residual imbalance, BMC Medical Research Methodology
Puhr, Heinze, Nold, Lusa, Geroldinger, Firth's logistic regression with rare events: accurate effect estimates and predictions?, Stat Med
Razonable, Horo, Hanson, Comparable Outcomes for Bebtelovimab and Ritonavir-Boosted Nirmatrelvir Treatment in High-Risk Patients With Coronavirus Disease-2019 During Severe Acute Respiratory Syndrome Coronavirus 2 BA.2 Omicron Epoch, The Journal of Infectious Diseases
Research, De, FDA updates Sotrovimab emergency use authorization
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop